Urology

Targeting neural transcription factor BRN2 in neuroendocrine tumours

One in eight men in Canada will be diagnosed with prostate cancer in their lifetime. Despite the availability of surgical, radiological and drug treatment options, many patients develop castration resistant prostate cancer (CRPC), an incurable disease which is especially resistant to drugs. In its most lethal form, drug resistant CRPC behaves like a neuroendocrine cancer, which is completely unresponsive to traditional prostate cancer therapies. 

Primary Investigator: 
Award Type: 
Year: 
2017
Health Category: 

Beyond the known genome: long non-coding RNAs as novel therapeutic targets and biomarkers for metastatic prostate cancer

Recent evidence indicates that non-coding RNAs (NC-RNAs) play crucial functions in physiological and pathological cellular processes. Long non-coding RNAs (lncRNAs) are the most abundant NC-RNA class, accounting for 10–20,000 genes. Despite this, the role of only a few of them (approxim. 40) has been characterized. Many lncRNAs show a tissue-specific expression pattern and are altered in cancer cells. For this reason, it has been suggested that they may be useful as biomarkers in oncology.

Primary Investigator: 
Award Type: 
Year: 
2013
Health Category: 

Adaptive stress response signaling driving treatment resistance and metastasis in cancer

Cancer deaths are driven by two key biological processes: metastasis and treatment resistance. Although these processes are extensively studied as unrelated occurrences, evidence of shared signaling networks suggests common genetic or adaptive events. These pathways will change a therapy-responsive tumour to a resistant and lethal tumour. This occurs in prostate cancer where strategies used to kill tumours induce adaptive responses promoting the emergence of treatment-resistant tumours prone to metastasize.

Primary Investigator: 
Award Type: 
Year: 
2012
Health Category: 
Subscribe to RSS - Urology